A scaled back version of a 2017 bill that sought to cap drug costs will instead follow a route successful in California, requiring drug manufacturers to explain big price increases
Rep. Rob Nosse, D-Portland, has found bipartisan, bicameral support for legislation to improve the price transparency for pharmaceuticals, giving momentum to passage that eluded advocates last year.
An ongoing controversy over generic equivalents to complex biological drugs is resurfacing in the 2016 session, as patient advocacy groups and drug companies try again to require pharmacists to take extra steps to notify prescribers of a substitution when they dispense something other than a brand-name biological drug.
Rep. Rob Nosse, D-Portland, is bringing back a bill that requires pharmacists to give extra notification to medication prescribers when the pharmacist dispenses a cheaper, biosimilar equivalent to a brand-name biological drug.
Kaiser Health News
Most Americans value the prescription products the drug industry produces, but they sure don’t like the prices and want the federal government to take action, according to a new survey.